Peregrine's Tarvacin Effective in Imaging Prostate Cancer

Peregrine Pharmaceuticals has reported data showing the potential use of Tarvacin, its lead anti-phospholipid therapy agent, for imaging solid tumors.

Data showed that Tarvacin could be used to deliver a radioactive arsenic compound to prostate cancer blood vessels for tumor imaging. Peregrine expects to begin patient enrollment in a Tarvacin Phase I clinical trial for the treatment of cancer within the next 30 days.